D-lactic acid inhibits Candida albicans associated with vulvovaginal candidiasis: in vitro and in vivo effects and underlying mechanisms Authors: Tingting Xia, Shujun Su, Rong Wu, Miaorong Zhan, Xuchu Hu, Huaiqiu Huang Published: 2025 ABSTRACT AbstractBackgroundCandida albicans (C. albicans) is a major opportunistic fungal pathogen responsible for both invasive and superficial infections, including vulvovaginal candidiasis (VVC), which affects a large proportion of women worldwide and is prone to recurrence. Limitations of conventional antifungal therapies and the emergence of drug resistance highlight the urgent need for novel therapeutic agents. D-lactic acid (D-LA), a chiral organic acid naturally produced by Lactobacillus spp., has been proposed as a potential antifungal candidate. However, its activity against C. albicans and underlying mechanisms remain unclear. Therefore, this study aimed to evaluate the antifungal activity of D-LA against C. albicans and to explore its potential mechanisms.MethodsC. albicans SC5314 was treated with D-LA in vitro to evaluate its effects on fungal growth, hyphal morphogenesis, and biofilm development using broth microdilution assays, hyphal induction/inhibition assays, crystal violet staining, and XTT-based metabolic activity measurement. Cell membrane integrity was assessed via trypan blue exclusion and live/dead fluorescent staining. RNA-seq and qRT-PCR were performed to identify differentially expressed genes and enriched functional pathways. The antifungal efficacy of D-LA was further evaluated in a mouse model of vaginal candidiasis.ResultsD-LA significantly inhibited hyphal formation and biofilm development in a concentration-dependent manner. Crystal violet and XTT assays confirmed substantial suppression of biofilm biomass and metabolic activity. Live/dead staining and trypan blue exclusion indicated increased cell membrane damage after D-LA exposure. Transcriptomic profiling revealed significant changes in genes related to hyphal development, cell wall organization, iron metabolism, acid phosphatase activity, and stress response. qRT-PCR validation demonstrated that the addition of D-LA downregulated virulence-associated genes (ECE1, TEC1, ALS1) and upregulated the pH-regulated gene PHR2 in C. albicans. Cytotoxicity testing on VK2/E6E7 vaginal epithelial cells indicated minimal toxicity at concentrations effective against C. albicans. In vivo antifungal efficacy and safety of D-LA in a mouse model of C. albicans vaginal infection demonstrating potent efficacy and a favorable profile.ConclusionD-LA exhibits potent antifungal activity against C. albicans by disrupting hyphal formation, biofilm development, and cell wall integrity, accompanied by transcriptional reprogramming of virulence-associated pathways. Its low cytotoxicity towards vaginal epithelial cells and mouse vaginal mucosa supports its potential as a safe alternative or adjunctive agent for VVC management.Keywords: D-lactic acid, Candida albicans, Vulvovaginal candidiasis, Biofilm, Transcriptomics, Hyphal formation Introduction In late 2022, the World Health Organization (WHO) released its inaugural Fungal Priority Pathogens List, categorizing 19 fungal species into critical, high, and medium priority groups. C. albicans was classified as a critical-priority pathogen [1], underscoring its global clinical importance. Furthermore, subsequent analyses have confirmed Candida spp. as critical-priority status when regional disease burden variations are considered [2]. Candida spp. are leading fungal pathogens, causing both invasive and superficial infections in patients at risk [3]. A critical virulence trait of C. albicans is its dimorphic switch from yeast to invasive hyphae [4]. ECE1 has long been recognized as a highly expressed, hypha-associated gene encoding the unique protein Ece1p (271 amino acids, 28.9 kDa) [5], and has been identified as a core filamentation gene that is expressed under most hypha-inducing conditions [6]. Key fungal regulators including TEC1 and ALS1 are essential for the virulence of C. albicans [7, 8]. PHR2, which encodes a GH72 enzyme, plays a critical role in enabling C. albicans to grow in acidic environments [9, 10]. Mucocutaneous candidiasis such as VVC affects an estimated 70–75% of women at least once during their lifetime [11]. Even more seriously, approximately 50% of affected women experience at least a second episode episodes, while nearly 10% of the female population suffers from chronic recurrent infections annually, the cumulative prevalence is high [12]. Although VVC is not life-threatening, its widespread occurrence, rising treatment expenses, and significant effects on patients’ well-being highlight the need for better understanding of its disease mechanisms, more effective treatments, and improved prevention of recurrent infections [13]. Conventional management of VVC primarily relies on antifungal formulations, including both oral and intravaginal preparations [14, 15]. Among these, azole-class antifungals represent the most commonly prescribed therapeutic agents [16]. However, despite their widespread clinical use, azole antifungals are frequently associated with adverse effects and demonstrate limited efficacy in achieving long-term cure [17]. Besides, although conventional antifungal therapies can effectively manage VVC, significant challenges persist, including ecosystem disturbances, drug intolerance, treatment failure, recurrent infections, and the emergence of drug-resistant Candida spp [18]. These limitations highlight the urgent need for alternative therapeutic approaches against VVC. Physiologically, the vaginal microbiota plays a crucial role in maintaining vaginal microecological balance and women’s reproductive health [19]. In a healthy eubiotic state, vaginal Lactobacillus crispatus, L. gasseri, and L. jensenii produce abundant lactic acid, which contributes to maintaining an acidic environment that protects against C. albicans overgrowth. Notably, Lactobacillus predominates as the key beneficial microbe [19]. Studies have shown that Lactobacillus species impair C. albicans biofilm development by disrupting early colonization, specifically through cell-cell interactions and the secretion of exometabolites that inhibit hyphal morphogenesis [20]. The antimicrobial activity of lactic acid bacteria is primarily mediated by the production of a diverse array of metabolites, including lactic acid, other organic acids, hydrogen peroxide, and bacteriocins [21]. There is evidence that the observed growth inhibition of C. albicans in co-culture with lactobacilli may be attributed to lactic acid produced by the lactobacilli at low pH [22]. In a healthy eubiotic state, lactobacilli produce abundant lactic acid. In vaginal eubiosis, lactobacilli maintain homeostasis through lactic acid production and antimicrobial secretion, establishing an acidic environment and protective biofilm that safeguards epithelial integrity [23, 24]. For this reason, growing research attention has focused on the therapeutic potential of lactic acid in VVC management [25, 26]. To date, however, the role of D-LA in modulating Candida-host interactions has not been elucidated. In this study, we systematically evaluated the antifungal activity and host compatibility of D-LA. Our results demonstrated that D-LA exerted potent, concentration-dependent inhibitory effects on C. albicans growth, hyphal formation, and biofilm development, while displaying minimal cytotoxicity toward vaginal epithelial cells at concentrations below 5 mg/mL. Transcriptomic and qRT-PCR analyses further revealed that D-LA modulates the expression of genes associated with hyphal development, cell wall biosynthesis, pH sensing, and stress responses, suggesting multiple mechanisms underlying its antifungal activity. Importantly, in vivo validation using a murine model of C. albicans vaginal infection confirmed the therapeutic efficacy of D-LA: intravaginal administration alleviated epithelial damage and reduced fungal burden in a dose-dependent manner, with 30 mg/mL D-LA showing robust antifungal activity without causing structural injury to vaginal mucosa. Collectively, these findings highlight D-LA as a promising candidate for the development of safe and effective therapeutic strategies against VVC. Materials and methods Fungal strains and growth conditions The C. albicans reference strain SC5314 was maintained on potato dextrose agar (PDA) plates at 30 °C. For inoculum preparation, colonies grown on PDA were harvested and resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, USA). The cell density was adjusted using a hemocytometer (Qiujing, Shanghai, China) to the desired concentration. Cell line and cell culture The VK2/E6E7 human vaginal epithelial cell line (ATCC CRL-2616), derived from the vaginal mucosa of a healthy premenopausal female, was used in this study. Cells were cultured in keratinocyte serum-free medium (KSFM; Gibco, USA; Cat. No. 17005042) supplemented with 50 µg/mL bovine pituitary extract (BPE) and 5 ng/mL epidermal growth factor (EGF). Cultures were maintained at 37 °C in a humidified incubator with 5% CO2 and subcultured every 3–4 days. Broth microdilution method The minimum inhibitory concentration (MIC) against C. albicans of D-LA was assessed by using a broth microdilution method under the guidance of Clinical and Laboratory Standards Institute (CLSI) according to the CLSI M27-A3 guideline [27]. The C. albicans strain was subcultured on PDA at 30 °C for 24 h. D-LA was purchased from Solarbio (D6190, C3H6O3, molecular weight: 90.08, density: 1.209 g/mL, purity: 90%, Beijing Solarbio, China). D-LA was soluble in RPMI 1640 medium. A fungal suspension was prepared in RPMI 1640 medium at a concentration of 2 × 103 CFU/mL, and 100 µL of this suspension was mixed with 100 µL of D-LA solution (20, 40 and 60 mg/mL in RPMI 1640). The final concentrations of D-LA were 10, 20, and 30 mg/mL, respectively. RPMI 1640 medium without D-LA served as the control. The mixtures were incubated in a 96-well microplate (Jet Biofil, China) at 37 °C for 24 h. In vitro fungicidal evaluation of D-LA C. albicans suspension (2 × 10⁶ CFU/mL in sterile H2O) was mixed 1:1 (v/v) with D-LA solutions at concentrations of 20, 40, and 60 mg/mL in sterile H2O. The final concentrations of D-LA were 10, 20, and 30 mg/mL respectively. Sterile H2O without D-LA served as the control. The mixtures were incubated at 37 °C for 4 h. Following incubation, 10 µL aliquots were serially diluted 1:1000 in sterile H2O, and 100 µL of each diluted suspension was spread onto PDA plates. Plates were incubated at 30 °C for 24 h and fungal viability was determined by CFUs using the standard plate count method [28]. Hyphal induction and Inhibition assays The hyphal formation and inhibition assays of C. albicans were performed according to the method of previous studies [29, 30] with slight modifications. Quantification of hyphal quantity of C. albicans was performed according to the method of Kurakado et al. [31, 32] with some modifications. Yeast-form C. albicans cells were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS; Punuosai, China) at a concentration of 2 × 10⁶ CFU/mL. Aliquots (500 µL) of the cell suspension were mixed with 500 µL of D-LA solution (5, 10, 20, 40, and 60 mg/mL in RPMI 1640). The final concentrations of D-LA were 2.5, 5, 10, 20, and 30 mg/mL, respectively. RPMI 1640 medium without D-LA served as the control. The mixtures were added to 12-well plates (Jet Biofil, China) and incubated on shaker at 200 rpm at 37 °C for 4 h. Hyphal morphology was observed using an inverted microscope equipped with a digital camera (Nikon, Japan). For the hyphal inhibition assay, yeast-form cells were first cultured at 1 × 10⁵ CFU/mL under the aforementioned conditions to form mature hyphae. The cultures were then transferred to 5 mL centrifuge tubes (Jet Biofil, China) and centrifuged at 1,000 rpm for 3 min. After removing the supernatant, the hyphal pellets were resuspended in different concentrations of D-LA (2.5, 5, 10, 20, and 30 mg/mL) and gently transferred to a 12-well plate, followed by additional incubation at 37 °C for 3 h. Hyphal morphology was recorded again using the inverted microscope. For each well, five randomly selected visual fields at 400× magnification was captured for quantitative analysis. Then calculate the mean number of C. albicans with hyphal growth and perform statistical analysis. Crystal Violet staining assay The antibiofilm activity of D-LA against C. albicans was evaluated using crystal violet staining [28]. Equal volumes (100 µL each) of C. albicans suspension (2 × 106 CFU/mL in RPMI 1640) and D-LA solutions (5, 10, 20, 40, and 60 mg/mL in RPMI 1640) were added to 96-well plates. The final concentrations of D-LA were 2.5, 5, 10, 20, and 30 mg/mL respectively. RPMI 1640 medium without D-LA served as the control. Plates were incubated at 37 °C for 24 h. After incubation, the supernatant was carefully removed, and each well was stained with 200 µL of 1% (w/v) crystal violet for 10 min at room temperature. Excess stain was removed by gently rinsing the wells three times with ultrapure water. Plates were air-dried, and biofilm formation was documented by digital photography. XTT reduction assay The metabolic activity of C. albicans biofilms was assessed using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)−5-[(phenylamino)carbonyl]−2 H-tetrazolium hydroxide (XTT) reduction assay (Solarbio, Beijing, China) [29]. To test the antibiofilm formation assay, equal volumes (100 µL each) of C. albicans suspension (2 × 106 CFU/mL in RPMI 1640) and D-LA solutions (5, 10, 20, 40, and 60 mg/mL in RPMI 1640) were added to 96-well plates. The final concentrations of D-LA were 2.5, 5, 10, 20, and 30 mg/mL respectively. RPMI 1640 medium without D-LA served as the control. Plates were incubated at 37 °C for 24 h. Following incubation, the supernatant was carefully removed, and 180 µL of PBS was added to each well. Subsequently, 20 µL of freshly prepared XTT working solution was added. The working solution was prepared by diluting 2 mL of XTT reagent according to the manufacturer’s instructions and adding 4 µL of electron-coupling reagent, followed by thorough mixing. Plates were incubated at 37 °C for 2 h in the dark. After incubation, absorbance was measured at a wavelength of 450 nm using a microplate reader to determine biofilm metabolic activity. The experiment was conducted with three technical replicates per group and was repeated five times as independent biological replicates. Subsequently, the mean optical density (OD450) of each group was calculated and statistically analyzed. In addition, for detecting the effect of D-LA on mature biofilms, C. albicans was added in 96-well plates and cultured for 24 h [33]. The liquid was gently aspirated, followed by a gentle wash with PBS. Subsequently, the biofilms were treated with varying concentrations of D-LA (2.5, 5, 10, 20, and 30 mg/mL) for an additional 3 h. The wavelength of 450 nm was then measured again using the XTT assay and subjected to statistical analysis, following the procedures described previously. Trypan blue staining assay Trypan blue staining was used to assess fungal cell viability, as non-viable cells take up the dye due to compromised membrane integrity [28]. C. albicans suspension (2 × 106 CFU/mL in sterile water) was mixed with an equal volume of D-LA solutions at concentrations of 20, 30, and 60 mg/mL in sterile water. The final concentrations of D-LA were 10, 20, and 30 mg/mL respectively. Sterile water without D-LA served as the control. The mixtures were incubated at 30 °C for 6 h. Following incubation, samples were centrifuged at 3,500 rpm for 5 min, and the pellets were washed once with sterile water under the same centrifugation conditions. The washed pellets were resuspended in 500 µL sterile water, mixed with 5 µL of 1% Trypan Blue solution (EcoTop Bio, China), and vortexed briefly. Staining was carried out for 10 min at room temperature, and dead C. albicans cells were quantified using a fully automated cell counter. Live/dead staining assay Live/dead staining was performed to visualize C. albicans cell viability, based on the principle that the membrane-impermeable dye propidium iodide (PI) stains non-viable cells, whereas the membrane-permeable dye 4′,6-diamidino-2-phenylindole (DAPI) stains all cells [28, 34]. C. albicans suspension (2 × 106 CFU/mL in sterile water) was mixed with an equal volume of D-LA solutions at final concentrations of 10, 20, 40, and 60 mg/mL in sterile water. The final concentrations of D-LA were 5, 10, 20, and 30 mg/mL. Sterile water without D-LA served as the control. The mixtures were incubated at 30 °C for 6 h, followed by centrifugation at 3,500 rpm for 5 min. Pellets were resuspended in 1 mL sterile water, washed once under the same centrifugation conditions, and then treated with 10 U lyticase in 1 mL sterile water at 37 °C for 5 min to partially digest the cell wall. Samples were centrifuged again (3,500 rpm, 5 min) and resuspended in 1 mL phosphate-buffered saline (PBS; Prosperich, China). Sequential staining was performed by adding 10 µL PI staining solution (EcoTop Bio, China) for 5 min, followed by 200 µL DAPI staining solution (EcoTop Bio, China) for 7 min at room temperature. After a final wash and centrifugation (3,500 rpm, 5 min), cells were resuspended in 1 mL PBS and transferred to confocal dishes (Jet Biofil, China). Imaging was performed using a laser scanning confocal microscope (ZEISS LSM 880 with Airyscan, Germany). Fungal transcriptomic sequencing analysis C. albicans suspension (2 × 10⁸ CFU/mL in RPMI 1640 medium) was mixed with D-LA solution at a 1:1 (v/v) ratio, achieving final D-LA concentrations of 10, 20, and 30 mg/mL in the coculture system (solvent: RPMI 1640 medium). RPMI 1640 medium without D-LA served as the control. The mixtures were incubated at 37 °C for 4 h, after which samples were immediately frozen in liquid nitrogen and sent to Guangdong Magigene Biotechnology Co., Ltd. (Guangdong, China) for eukaryotic transcriptome sequencing. RNA extraction, library preparation, and sequencing were performed by the service provider. Sequencing was conducted on an Illumina HiSeq 2500 platform (paired-end 150 bp reads). Each treatment group included four biological replicates. Raw sequencing reads were assessed for quality using FastQC (v0.12.1) [35]and summarized with MultiQC (v1.14) [36]. Adapter sequences and low-quality bases were trimmed using fastp (v0.23.4) [37] with default parameters. Clean reads were aligned to the C. albicans SC5314 reference genome (assembly A22, Candida Genome Database) using STAR (v2.7.10a) [38] in two-pass mode (--twopassMode Basic) with default settings for stranded RNA-seq. Alignment quality metrics, including mapping rate and read distribution, were evaluated with samtools (v1.17) [39]. Gene-level read counts were generated with featureCounts (Subread v2.0.3) using the corresponding GTF annotation, specifying the library strandedness and paired-end mode. Differential expression analysis was performed in DESeq2 (v1.38.3, R v4.2.2) [40], with differentially expressed genes (DEGs) defined as those with |log2 fold change| > 1 and adjusted p < 0.05 (Benjamini–Hochberg correction). Functional annotation and pathway enrichment analyses were conducted using clusterProfiler (v4.6.0) [41] with the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay To validate transcriptomic results and further investigate the antifungal mechanism of D-LA, qRT-PCR was performed to quantify the expression levels of ECE1, TEC1, ALS1, and PHR2. Total RNA was extracted from C. albicans and reverse-transcribed into cDNA using the Fast First-Strand cDNA Synthesis Mix for RT (COONIE, Guangzhou, China) according to the manufacturer’s instructions. Each qRT-PCR reaction (20 µL total volume) contained 0.4 µL forward primer, 0.4 µL reverse primer, 2 µL cDNA template, 7.2 µL RNase-free water, and 10 µL ChamQ Universal SYBR qPCR Master Mix (Vazyme, Nanjing, China). Amplification was performed on a real-time PCR system with the following program: initial denaturation at 95 °C for 30 s, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Primer sequences are listed in Table 1, with ACT1 used as the internal reference gene. All primers were synthesized and quality-validated (Sangon Biotech, Shanghai, China). The C. albicans SC5314 strain without D-LA treatment served as the control group. Relative gene expression levels were calculated using the method, where Table 1List of primers used for qRT-PCR analysis in this studyGenesPrimer nameSequence(5’−3’)ACT1[4]ACT1-FTCAGACCAGCTGATTTAGGTTTGACT1-RGTGAACAATGGATGGACCAGECE1[4]ECE1-FATCGAAAATGCCAAGAGAGECE1-RAGCATTTTCAATACCGACAGALS1[42]ALS1-FGACTAGTGAACCAACAAATACCAGAALS1-RCCAGAAGAAACAGCAGGTGATEC1[7]TEC1-FGCACTGGCTTCAAGCTCAAATEC1-RGCTGCTGCACTCAAGTTCTGPHR2[43]PHR2-FCTCCTCCATTTCCAGAACCAPHR2-RCGTCTGAATCAACCTTGTCG List of primers used for qRT-PCR analysis in this study In vitro cytotoxicity assay The cytotoxicity of D-LA toward VK2/E6E7 cells was evaluated using a Cell Counting Kit-8 (CCK-8; GLPBIO, USA) assay. Briefly, VK2/E6E7 cells were seeded in 96-well plates at 1.5 × 106 cells/mL (100 µL per well) and incubated at 37 °C for 24 h. The medium was then replaced with D-LA prepared in PBS (Yuanye, China) at final concentrations of 2.5, 5, 10, 20, and 30 mg/mL. Control wells received PBS without D-LA, while blank wells contained PBS only (no cells). Plates were incubated for an additional 2 h, after which the medium was replaced with KSFM containing 10% (v/v) CCK-8 reagent. Following 2 h incubation at 37 °C, absorbance at 450 nm was measured using a microplate reader. Cell viability (%) was calculated according to the following equation: where is the absorbance of the sample wells (cells + D-LA), is the absorbance of the control wells (cells + PBS), and is the absorbance of the blank wells (PBS only, no cells). Each group was replicated in five parallel samples. In vivo antifungal evaluation on C. albicans Healthy female ICR mice (6–8 weeks old, ~ 25 g) were obtained from the Experimental Animal Center, East Campus of Sun Yat-sen University (SCXK (Yue) 2021-0029, Guangzhou, China). The animals were housed under controlled conditions (26 °C, 50–70% humidity, 12 h light/dark cycle) with free access to standard chow and antibiotic-free water. All experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University (Approval No. SYSU-IACUC-2025-001833). After a one-week acclimatization period, mice were administered intramuscular injections of estradiol benzoate (0.05 mL/mouse; Ningbo Second Hormone Factory, Ningbo, China) every other day for 6 days. Vaginal infection was established by inoculating 25 µL of a C. albicans suspension (1 × 10⁸ CFU/mL in PBS) into the vaginal cavity. On day 4 post-inoculation, vaginal lavage was collected with 100 µL PBS, and the lavage fluid was subjected to PDA culture and Gram staining to confirm infection. Following verification, histological assessment of vaginal tissues was performed by Hematoxylin–Eosin (HE) and Periodic Acid–Schiff (PAS) staining. All invasive procedures were conducted under anesthesia with intraperitoneal injection of pentobarbital sodium (35 mg/kg). For therapeutic evaluation, mice were randomly assigned to different experimental groups. A total of 24 mice were assigned to groups of 3 mice each. The healthy control group consisted of uninfected and untreated mice, while an additional healthy + D-LA group (30 mg/mL) was included to assess drug safety in uninfected animals. Infected mice were further divided into a control group (infected but untreated), a PBS group (infected and treated with 50 µL PBS), and four treatment groups that received intravaginal administration of D-LA solutions at concentrations of 5, 10, 20, and 30 mg/mL (50 µL each, dispersed in PBS). All treatments were delivered once daily for seven consecutive days. At the end of the treatment period, mice were humanely euthanized, and vaginal tissues were harvested for HE and PAS staining to evaluate therapeutic efficacy. Statistical analysis All statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad Software, San Diego, CA, USA). Data are expressed as the mean ± standard deviation (SD) from at least three independent experiments. Comparisons between two groups were performed using an unpaired two-tailed Student’s t-test, while comparisons among multiple groups were conducted using one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. A p-value < 0.05 was considered statistically significant (p < 0.05, p < 0.01, p < 0.001). Results Dose-dependent inhibitory effect of D-LA on the growth of C. albicans The MIC of D-LA against C. albicans was determined to be 30 mg/mL. The antifungal activity was assessed in vitro using both OD590 measurements and a standard plate count assay. As shown in Fig. 1A, D-LA significantly reduced fungal biomass in a concentration-dependent manner, with OD590 values markedly lower at 10, 20, and 30 mg/mL compared with the untreated control (p < 0.05 to p < 0.0001). Consistently, plate count analysis (Fig. 1B) revealed a significant reduction in CFU/mL across all tested concentrations, with the greatest inhibition observed at 30 mg/mL (p < 0.001). Representative images from the plate assays (Fig. 1C) visually corroborated these quantitative findings, showing progressive suppression of C. albicans colony formation with increasing D-LA concentrations. These results demonstrate that D-LA exerts potent fungicidal effects against C. albicans, with efficacy evident even below its MIC, and maximal inhibition achieved at the MIC level. In vitro inhibitory effect of D-LA on the growth of C. albicans was incubated with D-LA at concentrations of 10, 20, and 30 mg/mL. A Growth inhibition in RPMI-1640 culture medium after treatment with D-LA (n = 5 independent experiments). B Following 4 h of incubation, CFU on PDA plates were significantly reduced in D-LA–treated groups compared with the untreated control (n = 4 independent experiments). C Representative PDA plates showing C. albicans colonies after incubation with D-LA at the indicated concentrations. Data in (A) and (B) are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test Inhibitory effects of D-LA on hyphal development in C. albicans For hyphal induction assays, D-LA markedly reduced hyphal formation in a dose-dependent manner, with significant suppression observed even at the lowest tested concentration compared with the untreated control (Fig. 2A, B). For hyphal inhibition assays, D-LA treatment resulted in a pronounced reduction in hyphal length and density compared with the control (Fig. 2C, D). Quantitative analysis confirmed a significant, concentration-dependent decrease in hyphal growth following D-LA exposure (p < 0.0001). Effects of D-LA on hyphal induction and inhibition in C. albicans. A Representative microscopic images (400× magnification) showing hyphal morphology after 4 h incubation at 37 °C in RPMI-1640 medium supplemented with 10% FBS and D-LA at 2.5, 5, 10, 20, and 30 mg/mL. B Quantification of hyphal induction following treatment with the indicated D-LA concentrations (n = 3 independent experiments). C Representative microscopic images (400× magnification) of preformed hyphae after 3 h exposure to D-LA (2.5, 5, 10, 20, and 30 mg/mL) at 37 °C. D Quantification of hyphal inhibition after D-LA treatment (n = 3 independent experiments). Data in (B) and (D) are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test In vitro antibiofilm activity and biosafety assessment of D-LA The antibiofilm activity of D-LA against C. albicans was evaluated using crystal violet staining and the XTT reduction assay. As shown in Fig. 3A, C and D-LA significantly inhibited biofilm formation in a dose-dependent manner, with measurable inhibition observed at concentrations as low as 2.5 mg/mL (p < 0.0001). Quantitative analysis demonstrated a significant reduction in the biomass of mature C. albicans biofilms following D-LA treatment (Fig. 3D). Trypan blue staining further demonstrated a marked increase in the proportion of non-viable fungal cells after D-LA exposure, with the highest mortality observed at 30 mg/mL (Fig. 3B). Biosafety was assessed by determining D-LA cytotoxicity toward mammalian cells. As shown in Fig. 3E, D-LA exhibited minimal cytotoxic effects, with cell viability exceeding 90% at concentrations up to 5 mg/mL. Representative fluorescence microscopy images (Fig. 3F) using DAPI/PI staining confirmed the selective antifungal activity of D-LA, showing increased red fluorescence (PI-positive dead fungal cells) in treated groups. In vitro antibiofilm activity and biosafety assessment of D-LA against C. albicans. A Representative crystal violet staining images of C. albicans biofilms after treatment with D-LA at the indicated concentrations. B Proportion of C. albicans cells stained with trypan blue following D-LA treatment (n = 3 independent experiments). C Quantitative analysis of biofilm biomass inhibition and (D) reduction of mature biofilms after D-LA exposure, measured using the XTT reduction assay (n = 5 independent experiments). E Viability of VK2 cells following incubation with D-LA (2.5, 5, 10, 20, and 30 mg/mL), determined by the CCK-8 assay (n = 3 independent experiments). F Fluorescence microscopy images of C. albicans after D-LA treatment. Cells were stained with DAPI (blue, total cells) and propidium iodide (PI; red, dead cells). Data in panels (B–E) are presented as mean ± SD. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test Transcriptomic analysis of the fungicidal mechanism of D-LA To elucidate the molecular mechanisms underlying the antifungal activity of D-LA, C. albicans cells were exposed to increasing concentrations of D-LA (10, 20, and 30 mg/mL) and subjected to transcriptomic sequencing. Compared with the untreated control, D-LA induced a concentration-dependent alteration in gene expression, with 49 genes upregulated and 68 genes downregulated at 10 mg/mL (Fig. 4A), 134 upregulated and 153 downregulated at 20 mg/mL (Fig. 4B), and 232 upregulated and 272 downregulated at 30 mg/mL (Fig. 4C). Functional enrichment analysis was performed to characterize the affected biological processes and pathways. The top 30 significantly enriched KEGG pathways are presented as bubble plots, ranked by p-value and enrichment score. KEGG enrichment analysis demonstrated that D-LA prominently perturbed several metabolic pathways, including thiamine metabolism (adjusted p = 0.0042), riboflavin metabolism (adjusted p = 0.0585), folate biosynthesis (adjusted p = 0.0585), β-alanine metabolism (adjusted p = 0.0822), and methane metabolism (adjusted p = 0.0822) (Fig. 4D-F). GO annotation revealed significant modulation of pathways related to transmembrane transport, cell wall organization, and stress response following D-LA treatment (Fig. 4G-I). A subset of key genes involved in hyphal and biofilm development, cell wall biosynthesis, acid phosphatase metabolism, iron homeostasis, stress response, and pH sensing displayed pronounced expression changes in a dose-dependent manner (Fig. 4J), highlighting potential targets through which D-LA exerts its antifungal effects. Transcriptomic profiling of C. albicans in response to D-LA treatment. A–C Volcano plots showing DEGs in C. albicans treated with D-LA at 10, 20, and 30 mg/mL compared with the untreated control. Upregulated genes are shown in red, downregulated genes in green, and non-significant genes in grey. D–F KEGG enrichment analysis of DEGs for the 10, 20, and 30 mg/mL D-LA treatments, highlighting the top enriched pathways ranked by enrichment factor and p-value. G–I GO functional annotation of DEGs for the corresponding treatment concentrations, displaying the top enriched biological processes, cellular components, and molecular functions. J Heatmap illustrating dose-dependent expression changes of key DEGs associated with hyphal and biofilm development, cell wall biosynthesis, acid phosphatase metabolism, iron homeostasis, stress response, and pH-sensing pathways. The statistical significance of pathway enrichment was assessed using the Benjamini–Hochberg method for multiple-test correction. Pathways with adjusted p values < 0.05 were considered statistically significant. As shown in Fig. 4D–I, the top enriched KEGG pathways displayed adjusted p values ranging from 2.4 × 10⁻³ to 4.7 × 10⁻⁵, while GO enrichment terms exhibited adjusted p values between 1.2 × 10⁻² and 3.6 × 10⁻⁴, indicating strong statistical significance across functional categories such as amino acid metabolism, glycolysis/gluconeogenesis, transmembrane transport, and cell wall organization. Validation of transcriptomic results by qRT-PCR To validate the transcriptomic findings, qRT-PCR was performed to assess the expression of selected hypha-specific and pH-regulated genes in C. albicans following D-LA treatment (n = 5 independent experiments). As shown in Fig. 5A, the expression levels of ECE1, TEC1, and ALS1 were significantly downregulated in a dose-dependent manner compared with the control group (p < 0.0001). In contrast, the pH-responsive gene PHR2 was markedly upregulated after D-LA exposure, with the highest expression observed at 30 mg/mL (Fig. 5B). These results are consistent with the transcriptomic analysis, confirming that D-LA modulates key genes involved in hyphal development and pH adaptation in C. albicans. The primer sequences used in this study are listed in Table 1. qRT-PCR validation of transcriptomic data in C. albicans following D-LA treatment (n = 5 independent experiments). Gene expression levels are presented as fold change relative to the untreated control. Data are shown as mean ± SD. A Relative expression of hypha-specific genes (ECE1, TEC1, and ALS1) in response to D-LA at the indicated concentrations. B Relative expression of the pH-responsive gene PHR2 following D-LA exposure In vivo therapeutic effect of D-LA against vaginal fungal infections Building upon the superior fungicidal activity of D-LA observed in vitro, a mouse vaginal infection model was established through intravaginal inoculation of C. albicans SC5314 to evaluate its antifungal efficacy in vivo. On day 7 of treatment, mice receiving intravaginal D-LA exhibited marked improvement in vaginal infection compared with untreated and PBS-treated controls. Histopathological examination further confirmed the therapeutic effects: HE and PAS staining demonstrated that D-LA administration substantially reduced epithelial damage and fungal burden in a dose-dependent manner (Fig. 6). Notably, vaginal tissues from mice treated with 30 mg/mL D-LA showed intact epithelial architecture without evidence of structural injury, indicating both potent antifungal efficacy and favorable safety profiles in vivo. In vivo antifungal efficacy and safety of D-LA in a mouse model of C. albicans vaginal infection. Representative HE and PAS staining of vaginal tissues from mice in different treatment groups. D-LA treatment alleviated epithelial damage and reduced fungal burden in a dose-dependent manner, while 30 mg/mL D-LA caused no structural injury to vaginal mucosa, confirming both therapeutic efficacy and safety Discussion VVC is a common gynecological inflammatory disease with a high recurrence rate, primarily caused by C. albicans [3]. The azole antifungal agents currently employed in the treatment of VVC are associated with notable adverse effects, including hypersensitivity reactions, and demonstrate significant drug-drug interactions [44]. Several studies proved that lactic acid bacteria (LAB) of vaginal and oral inhibit growth and hyphae formation of C. albicans through multiple synergistic mechanisms [45, 46]. Primarily, LAB produce a combination of toxic organic acids (with lactic acid being predominant), hydrogen peroxide (H₂O₂), and various antifungal metabolites that directly inhibit fungal viability [47, 48]. Additionally, through the secretion of these organic acids, LAB significantly acidify the local microenvironment, creating pH conditions that effectively suppress filamentation in white-phase C. albicans cells [49]. These dual antimicrobial strategies, which are direct biochemical inhibition and environmental modification, collectively constitute a robust biological defense system against C. albicans colonization and pathogenesis. Das et al. reported that the probiotic culture free supernatant from Lactobacillus crispatus, L. gasseri, and L. vaginalis exhibit an inhibitory effect on budding, hyphae, and biofilm formation of C. albicans, which is consistent with our results. We show that D-LA exerts potent inhibitory effects on hyphal morphogenesis and subsequent filamentous growth, which may be attributed to its role as a key antimicrobial component in the cell-free supernatant of vaginal LAB [50]. However, the presence of low dose lactic acid in vaginal simulative medium increased C. albicans proliferation, hyphal length, and its ability to cause damage during subsequent infection of vaginal epithelial cells [51]. This phenomenon may be attributed to L-lactate triggering β-glucan masking in pathogenic Candida spp [25]. The discrepancy between the observed phenomenon and our findings may be attributed to the higher concentration of D-LA used in our study. The clinical significance of C. albicans is largely attributed to its capacity for biofilm formation and structured microbial communities characterized by surface-adherent cellular aggregates that colonize both biological tissues and abiotic medical implants [52]. Our data demonstrate that D-LA significantly inhibits both biofilm formation and disrupts pre-existing mature biofilms of C. albicans. ECE1, TEC1 and ALS1 plays a positive role in C. albicans hyphal development [4, 7]. The hypha-specific expression of ECE1 (extent of cell elongation) in C. albicans produces Ece1p, a secreted effector protein essential for inducing epithelial cell activation and subsequent tissue damage during infection [4, 53]. In the present study, we have demonstrated that D-LA significantly suppresses the relative quantitative expression of ECE1, TEC1 and ALS, consequently inhibiting hyphal growth in C. albicans. C. albicans PHR2 is an acid-responsive gene encoding a glycosyl hydrolase family 72 (GH72) enzyme essential for β−1,3 and β−1,6-glucans crosslinking in the fungal cell wall [10]. Rim101 orchestrates pH-dependent transcriptional reprogramming through differential regulation of target genes-positively regulating alkaline-responsive genes including PHR1 while negatively controlling acid-responsive genes such as PHR2 [54, 55]. We observed that under increasing concentrations of D-LA, PHR2 expression demonstrates a dose-dependent induction pattern, which is consistent with previous results [10]. Previous studies have demonstrated that oral administration of sodium D-lactate (1000 mg/kg) in mice is safe, effectively addressing prior concerns regarding its toxicity. Moreover, dietary D-lactate has been suggested as a previously unrecognized nutritional compound that facilitates the resolution of acute inflammation [56]. In the present study, we examined the effect of D-LA on vaginal epithelial cells. Our results revealed that D-LA significantly inhibited the viability of human vaginal epithelial cells at higher concentrations, whereas no morphological alterations were observed at concentrations below 5 mg/mL. This phenomenon may reflect the intrinsic fragility of vaginal epithelial cells under in vitro culture conditions. This study is subject to some limitations. Notably, our conclusions are drawn largely from experiments using the standard laboratory strain SC5314 and thus may not fully capture the nuances of the in vivo host environment or the pathogenicity of clinical strains in human VVC. Additionally, the exact molecular mechanisms and targets through which D-LA induces the observed transcriptional changes remain to be fully elucidated. Conclusions In summary, D-LA exhibited either fungistatic or fungicidal effects against C. albicans, significantly inhibiting hyphal formation and growth. It also suppressed biofilm formation and disrupts mature biofilms. Transcriptome sequencing and qRT-PCR analysis revealed potential molecular targets, suggesting that its mechanism of action may be associated with alterations in fungal cell wall structure. Low concentrations of D-LA did not affect the morphology and viability of the VK2 cells. These findings position D-LA as a promising safe and effective therapeutic candidate for VVC treatment, warranting further investigation into its clinical applicability. Acknowledgements We thank Professor Xiaodong She (the Chinese Academy of Medical Sciences, Nanjing, China.) for providing the C. albicans strain (SC5314) and VK2 E6/E7 cell line. Institutional review board statement The Institutional Animal Care and Use Committee of Sun Yat-sen University. Authors’ contributions T.X. Data curation, Investigation, Methodology, Writing–original draft, Writing–review & editing. S.S. Investigation, Methodology, Writing–review & editing. R.W. Investigation, Methodology. M.Z. Visualization, Methodology. X.H. Conceptualization, Resources, Project administration. H.H. Conceptualization, Data curation, Investigation, Validation, Writing–review & editing, Funding acquisition, Resources, Project administration. All authors read and approved the final manuscript. Funding This research was funded by the National Natural Science Foundation of China (U24A20745) and the Key Research and Development Plan of the Guangzhou Science and Technology Bureau (2024B01J1191). Data availability Data AvailabilityThe raw data generated in this study are available upon reasonable request from the corresponding authors. Raw RNA-seq data have been deposited in the NCBI SRA under BioProject PRJNA1372024 and SRA Study SRP650209. All individual samples and sequencing runs associated with this project are publicly available at: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1372024. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Tingting Xia and Shujun Su contributed equally to this work. Contributor Information Xuchu Hu, Email: huxuchu@mail.sysu.edu.cn. Huaiqiu Huang, Email: hhuaiq@mail.sysu.edu.cn. References Associated Data Data Availability Statement Data AvailabilityThe raw data generated in this study are available upon reasonable request from the corresponding authors. Raw RNA-seq data have been deposited in the NCBI SRA under BioProject PRJNA1372024 and SRA Study SRP650209. All individual samples and sequencing runs associated with this project are publicly available at: https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1372024.